⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024Cancer MedicineOpen Access

Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer

Wentao Tian Lishui Niu Rongrong Zhou Ziqi Wang Jiaoyang Ning Ruoyu Lu Yin Shi Zhaohua Tan

View Full Paper

Ask AI

Bookmark

Share

Abstract

First-line osimertinib plus chemotherapy significantly prolonged progression-free survival of patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib, according to the FLAURA2 trial.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tian et al. (2024) studied this question.

synapsesocial.com/papers/68e5e2bab6db64358757751b https://doi.org/10.1002/cam4.70083

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Survival with Osimertinib plus Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC2025 · 118 citations
2Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung CancerOriginal Research · 2026 · 2 citations
3First-line osimertinib with or without chemotherapy for EGFR-mutant advanced NSCLC in China: a cost-effectiveness analysisOriginal Research · 2026
4A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective studyRetrospective Study · 2021 · 15 citations
5First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation–positive non–small cell lung cancer: protocol for a multicenter, prospective, observational study2025

More related papers

TOP: A phase III, multicentre, randomized controlled study comparing osimertinib in combination with carboplatin and pemetrexed to osimertinib monotherapy for untreated patients with advanced non-squamous (Non-sq) non-small cell lung cancer (NSCLC) with concurrent EGFR and TP53 mutations.2024
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC2019
Cost-effectiveness of amivantamab plus lazertinib and osimertinib plus chemotherapy versus osimertinib monotherapy for first-line EGFR‐mutated advanced Non‐small cell lung cancer: an updated analysis2026

More from Cancer Medicine

The Effect of Prophylactic Protection of Inferior Parathyroid Gland Vein Blood Supply on Reducing Postoperative HypoparathyroidismThu,
Self‐Reported Cancer‐Related Cognitive Impairment and Psychosocial Symptom Burden in Survivors of Head and Neck CancerWed,